• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
75,237.99 -160.73
( -0.21%)
Global Indices
Nasdaq
49,543.85 -540.61
(-1.08%)
Dow Jones
7,428.26 -93.98
(-1.25%)
Hang Seng
61,141.50 -1,512.55
(-2.41%)
Nikkei 225
10,172.40 -200.53
(-1.93%)
Forex
USD-INR
95.71 0.07
(0.07%)
EUR-INR
111.93 -0.13
(-0.12%)
GBP-INR
129.01 -0.31
(-0.24%)
JPY-INR
0.61 0.00
(-0.09%)

EQUITY - MARKET SCREENER

Aptus Pharma Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
544529
INE15XJ01010
11.6537026
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
317.28
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

mrf ltd
Ashok Leyland’s total sales climb 9% YoY to 14,646 units in April’26
May 04,2026
Total medium & heavy commercial vehicle (M&HCV) sales jumped 4% YoY to 8,302 units in April 2026, while light commercial vehicle (LCV) sales climbed 16% YoY to 6,344 units in April 2026.

In the domestic market, total vehicle sales increased 14% YoY to 14,242 units in April 2026, compared with 12,509 units in April 2025. Domestic M&HCV sales rose 8% YoY to 7,977 units, while LCV sales climbed 23% YoY to 6,265 units.

Ashok Leyland is involved in the manufacture and sale of a broad range of commercial vehicles and also makes engines for industrial and marine applications, as well as forgings and castings.

The company’s consolidated net profit increased 6.8% YoY to Rs 813.49 crore in Q3 FY26 compared with Rs 761.92 crore in Q3 FY25. Net sales jumped 23.6% to Rs 14,761.95 crore in the quarter ended 31st December 2025.

The scrip rose 0.03% to Rs 162.15 on the BSE.